UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE PATENT TRIAL AND APPEAL BOARD
MODERNA THERAPEUTICS, INC., Petitioner,
v.
PROTIVA BIOTHERAPEUTICS, INC., Patent Owner.
Case IPR2018-00739
Patent No. 9,364,435

DECLARATION OF DAVID H. THOMPSON, PH. D.



TABLE OF CONTENTS

I.	QUALIFICATIONS				
II.	SCOPE OF WORK				
III.	LEGAL STANDARDS				
IV.	LEVEL OF ORDINARY SKILL IN THE ART				
V.	BACKGROUND				
VI.	CLAIM CONSTRUCTION				
VII.	GROUND 1 – CLAIMS 1-20 ARE NOT OBVIOUS IN VIEW OF PATENT OWNER'S DISCLOSURES IN THE '196 PCT AND '189 PUBLICATION				
	A.	Claim 1	16		
	B.	Unexpected Results	22		
	C.	Claims 2-20	31		
VIII.	PAT	OUND 2 – CLAIMS 1-20 ARE NOT OBVIOUS IN VIEW OF ENT OWNER'S PRIOR DISCLOSURES IN LIGHT OF LIN O/OR AHMAD	38		
IX.	GROUND 3 – CLAIMS 1-20 ARE NEITHER ANTICIPATED BY NOR OBVIOUS IN VIEW OF THE '554 PUBLICATION				
	A.	Claim 1	45		
		1. Anticipation by L054	45		
		2. Anticipation by ranges	52		
		3. Obvious over ranges	56		
	B.	Claims 2-20	58		
Χ.	OBJECTIVE INDICIA OF NONOBVIOUSNESS				
	A.	Long-felt need	72		



	В.	Skepticism	76
	C.	Unexpected Results	77
	D.	Commercial Success	83
ΧI	CON	JCLUDING STATEMENTS	84



I, David H. Thompson, declare as follows:

I. QUALIFICATIONS

- 1. I am a Professor of Chemistry at Purdue University and Director of the Medicinal Chemistry Group in the Purdue Center for Cancer Research. My primary research interests include development of transiently-stable carrier systems for drug and nucleic acid delivery.
- I received my Ph.D. in Organic Chemistry from Colorado State
 University in 1984. I also hold a Bachelor of the Arts in Biology and a Bachelor of
 Science in Chemistry from the University of Missouri, Columbia.
- 3. I have been a visiting professor at numerous institutions including, Chulalongkorn University, Department of Pharmaceutics; Technical University of Denmark, Department of Micro & Nanotechnology; Japan Advanced Institute of Science & Technology, Department of Biomaterials; Osaka University, Department of Applied Chemistry; University of Florida, Department of Pharmaceutics; and University of British Columbia, Department of Biochemistry.
- 4. I am listed as a co-inventor on 7 United States patents. I have also published more than 140 peer reviewed scientific papers.
- 5. I have studied, taught, practiced, and conducted research involving the formulation, use, characterization, and delivery of lipid particles. I have expertise with the delivery of therapeutic agents using lipid particles.



6. A copy of my Curriculum Vitae, attached as EX2010, contains further details on my education, experience, publications, and other qualifications to render an expert opinion in this matter.

II. SCOPE OF WORK

- 7. I understand that a petition was filed with the United States Patent and Trademark Office for inter partes review of U.S. Patent No. 9,364,435 ("the '435 patent," EX1001).
- 8. I further understand that the Patent Trial and Appeal Board ("PTAB" or the "Board") has decided to institute inter partes review of claims 1-20 of the '435 patent under 35 U.S.C. §§ 102 and 103 based on the disclosures of WO2005/007196 ("the '196 PCT," EX1002), US 2006/134189 ("the '189 PCT," EX1003), Lin, et al, "Three-Dimensional Imaging of Lipid Gene-Carriers: Membrane Charge Density Controls Universal Transfection Behavior in Lamellar Cationic Liposome-DNA Complexes," ("Lin," EX1005), Ahmad, et al, "New multivalent cationic lipids reveal bell curve for transfection efficiency versus membrane charge density: lipid–DNA complexes for gene delivery," ("Ahmad," EX1006), and US 2006/0240554 ("the '554 publication," EX1004).
- 9. I have been specifically asked to provide my expert opinions on the patentability of the claims of the '435 patent in view of the asserted grounds in the petition. In connection with this analysis, I have reviewed the '435 patent and the



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

